• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

4期神经母细胞瘤患者的间碘苄胍(MIBG)扫描显示出两种转移模式,一种与MYCN扩增相关,在MYCN扩增的肿瘤中与较好的预后相关。

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

作者信息

Bleeker Gitta, van Eck-Smit Berthe L, Zwinderman Koos H, Versteeg Rogier, van Noesel Max M, Kam Boen L, Kaspers Gertjan J, van Schie Annelies, Kreissman Susan G, Yanik Gregory, Hero Barbara, Schmidt Matthias, Laureys Geneviève, Lambert Bieke, Øra Ingrid, Schulte Johannes H, Caron Huib N, Tytgat Godelieve A

机构信息

Department of Paediatric Oncology, Academic Medical Centre/Emma Children's Hospital, PO Box 22700, 1100 DE, Amsterdam, The Netherlands.

出版信息

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):222-30. doi: 10.1007/s00259-014-2909-1. Epub 2014 Sep 30.

DOI:10.1007/s00259-014-2909-1
PMID:25267348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4315489/
Abstract

PURPOSE

The aim of this study was to find clinically relevant MIBG-avid metastatic patterns in patients with newly diagnosed stage 4 neuroblastoma.

METHODS

Diagnostic (123)I-MIBG scans from 249 patients (123 from a European and 126 from the COG cohort) were assessed for metastatic spread in 14 body segments and the form of the lesions: "focal" (clear margins distinguishable from adjacent background) or "diffuse" (indistinct margins, dispersed throughout the body segment). The total numbers of diffuse and focal lesions were recorded. Patients were then categorized as having lesions exclusively focal, lesions more focal than diffuse, lesions more diffuse than focal, or lesions exclusively diffuse.

RESULTS

Diffuse lesions affected a median of seven body segments and focal lesions a median of two body segments (P < 0.001, both cohorts). Patients with a focal pattern had a median of 2 affected body segments and those with a diffuse pattern a median of 11 affected body segments (P < 0.001, both cohorts). Thus, two MIBG-avid metastatic patterns emerged: "limited-focal" and "extensive-diffuse". The median numbers of affected body segments in MYCN-amplified (MNA) tumours were 5 (European cohort) and 4 (COG cohort) compared to 9 and 11, respectively, in single-copy MYCN (MYCNsc) tumours (P < 0.001). Patients with exclusively focal metastases were more likely to have a MNA tumour (60% and 70%, respectively) than patients with the other types of metastases (23% and 28%, respectively; P < 0.001). In a multivariate Cox regression analysis, focal metastases were associated with a better event-free and overall survival than the other types of metastases in patients with MNA tumours in the COG cohort (P < 0.01).

CONCLUSION

Two metastatic patterns were found: a "limited and focal" pattern found mainly in patients with MNA neuroblastoma that correlated with prognosis, and an "extensive and diffuse" pattern found mainly in patients with MYCNsc neuroblastoma.

摘要

目的

本研究旨在探寻新诊断的4期神经母细胞瘤患者中具有临床相关性的间碘苄胍(MIBG)摄取阳性转移模式。

方法

对249例患者(欧洲队列123例,儿童肿瘤协作组[COG]队列126例)的诊断性(123)I-MIBG扫描进行评估,观察其在14个身体部位的转移扩散情况以及病变形态:“局灶性”(边界清晰,可与相邻背景区分)或“弥漫性”(边界不清,散布于整个身体部位)。记录弥漫性和局灶性病变的总数。然后将患者分为仅具有局灶性病变、局灶性病变多于弥漫性病变、弥漫性病变多于局灶性病变或仅具有弥漫性病变。

结果

弥漫性病变累及的身体部位中位数为7个,局灶性病变为2个(两个队列P均<0.001)。具有局灶性模式的患者受累身体部位中位数为2个,具有弥漫性模式的患者为11个(两个队列P均<0.001)。由此出现了两种MIBG摄取阳性转移模式:“局限性局灶性”和“广泛性弥漫性”。与MYCN单拷贝(MYCNsc)肿瘤相比,MYCN扩增(MNA)肿瘤受累身体部位的中位数在欧洲队列中为5个,在COG队列中为4个,而在MYCNsc肿瘤中分别为9个和11个(P<0.001)。与其他类型转移的患者(分别为23%和28%)相比,仅具有局灶性转移的患者更有可能患有MNA肿瘤(分别为60%和70%;P<0.001)。在多因素Cox回归分析中,在COG队列的MNA肿瘤患者中,局灶性转移与更好的无事件生存期和总生存期相关(P<0.01)。

结论

发现了两种转移模式:主要在与预后相关的MNA神经母细胞瘤患者中发现的“局限性和局灶性”模式,以及主要在MYCNsc神经母细胞瘤患者中发现的“广泛性和弥漫性”模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/52d849073986/259_2014_2909_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/fd8f77ff6980/259_2014_2909_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/73de6fda2add/259_2014_2909_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/6ded7f0239cd/259_2014_2909_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/52d849073986/259_2014_2909_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/fd8f77ff6980/259_2014_2909_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/73de6fda2add/259_2014_2909_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/6ded7f0239cd/259_2014_2909_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/382d/4315489/52d849073986/259_2014_2909_Fig4_HTML.jpg

相似文献

1
MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.4期神经母细胞瘤患者的间碘苄胍(MIBG)扫描显示出两种转移模式,一种与MYCN扩增相关,在MYCN扩增的肿瘤中与较好的预后相关。
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):222-30. doi: 10.1007/s00259-014-2909-1. Epub 2014 Sep 30.
2
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.间碘苄胍摄取与神经母细胞瘤的临床特征、肿瘤生物学及预后的相关性:儿童肿瘤协作组报告
Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26545. Epub 2017 Apr 6.
3
Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.神经母细胞瘤中异质 MYCN 扩增与临床特征、生物学特征和结局的关系:来自儿童肿瘤协作组的报告。
Eur J Cancer. 2020 Jul;133:112-119. doi: 10.1016/j.ejca.2020.04.007. Epub 2020 May 31.
4
In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.神经母细胞瘤患者的铟-111 奥曲肽闪烁扫描。与碘-131 间碘苄胍、N - 原癌基因扩增及患者预后的比较。
Clin Nucl Med. 1997 May;22(5):315-9. doi: 10.1097/00003072-199705000-00008.
5
Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.利用血清DNA和实时定量聚合酶链反应预测神经母细胞瘤中的MYCN扩增
J Clin Oncol. 2005 Aug 1;23(22):5205-10. doi: 10.1200/JCO.2005.02.014.
6
Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.MYCN基因扩增和倍性在预后良好型神经母细胞瘤中的临床意义:来自儿童肿瘤研究组的报告
J Clin Oncol. 2008 Feb 20;26(6):913-8. doi: 10.1200/JCO.2007.13.9493.
7
Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.DDX1的共扩增与MYCN扩增的人类神经母细胞瘤患儿的生存概率提高相关。
J Clin Oncol. 2004 Jul 1;22(13):2681-90. doi: 10.1200/JCO.2004.07.192.
8
The Association between Tumour Markers and Meta-iodobenzylguanidine Scans in South African Children with High-risk Neuroblastoma.南非高危神经母细胞瘤患儿肿瘤标志物与间碘苄胍扫描之间的关联。
Clin Oncol (R Coll Radiol). 2021 Aug;33(8):517-526. doi: 10.1016/j.clon.2021.03.003. Epub 2021 Mar 26.
9
Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.放射性碘化间碘苄胍在儿童神经母细胞瘤诊断中的应用
Q J Nucl Med. 1995 Dec;39(4 Suppl 1):21-4.
10
Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.神经母细胞瘤在诊断、治疗、复发和转移时MYCN扩增的异质性。
Genes Chromosomes Cancer. 2017 Jan;56(1):28-41. doi: 10.1002/gcc.22398. Epub 2016 Aug 18.

引用本文的文献

1
Urinary Catecholamines Predict Relapse During Complete Remission in High-Risk Neuroblastoma.尿儿茶酚胺可预测高危神经母细胞瘤完全缓解期的复发情况。
JCO Precis Oncol. 2025 Jan;9:e2400491. doi: 10.1200/PO-24-00491. Epub 2025 Feb 21.
2
Dilemmas in the Management of an Infant with Neuroblastoma Metastasized to the Muscles.一名神经母细胞瘤转移至肌肉的婴儿的治疗困境
Case Rep Oncol. 2023 Jul 26;16(1):558-567. doi: 10.1159/000531433. eCollection 2023 Jan-Dec.
3
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.

本文引用的文献

1
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.半定量 mIBG 评分作为 4 期神经母细胞瘤患者的预后指标:来自儿童肿瘤学组的报告。
J Nucl Med. 2013 Apr;54(4):541-8. doi: 10.2967/jnumed.112.112334. Epub 2013 Feb 25.
2
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.碘-123 间碘苄胍闪烁扫描评分可预测Ⅳ期神经母细胞瘤患者的预后:科隆国际评分比较研究结果。
J Clin Oncol. 2013 Mar 1;31(7):944-51. doi: 10.1200/JCO.2012.45.8794. Epub 2013 Jan 22.
3
诊断和诱导结束居里分数对高危转移性神经母细胞瘤患者行串联高剂量化疗和自体移植的影响:来自儿童肿瘤学组的报告。
Pediatr Blood Cancer. 2023 Aug;70(8):e30418. doi: 10.1002/pbc.30418. Epub 2023 May 18.
4
Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.神经母细胞瘤的放射基因组学:影像学表型、肿瘤基因组特征与生存之间的关系。
PLoS One. 2017 Sep 25;12(9):e0185190. doi: 10.1371/journal.pone.0185190. eCollection 2017.
5
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.间碘苄胍摄取与神经母细胞瘤的临床特征、肿瘤生物学及预后的相关性:儿童肿瘤协作组报告
Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26545. Epub 2017 Apr 6.
6
Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma.眼眶转移与M期神经母细胞瘤患者生存率降低相关。
Pediatr Blood Cancer. 2016 Apr;63(4):627-33. doi: 10.1002/pbc.25847. Epub 2015 Nov 24.
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
功能型 MYCN 特征可预测神经母细胞瘤的预后,而与 MYCN 扩增无关。
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.
4
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.神经母细胞瘤中去甲肾上腺素转运体表达及间碘苄胍亲和力的评估:来自儿童肿瘤研究组的报告
Int J Mol Imaging. 2012;2012:250834. doi: 10.1155/2012/250834. Epub 2012 Sep 25.
5
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.在高危神经母细胞瘤患儿中,作为 HR-NBL-1/SIOPEN 试验的一部分,接受大剂量骨髓清除化疗后,静脉和口服给予白消安的药代动力学。
Eur J Cancer. 2012 Nov;48(16):3063-72. doi: 10.1016/j.ejca.2012.05.020. Epub 2012 Jun 26.
6
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.¹²³I-间碘苄胍(MIBG)与 ¹³¹I-MIBG 半定量评分在预测 4 期神经母细胞瘤患者生存中的比较:来自儿童肿瘤学组的报告。
Pediatr Blood Cancer. 2011 Jul 1;56(7):1041-5. doi: 10.1002/pbc.22991. Epub 2011 Feb 15.
7
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.131I/123I-间碘苄胍(mIBG)闪烁显像:肿瘤显像程序指南。
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2436-46. doi: 10.1007/s00259-010-1545-7.
8
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.(123)I-间碘苄胍扫描评估神经母细胞瘤疾病程度的标准:国际神经母细胞瘤风险组(INRG)工作组报告。
Br J Cancer. 2010 Apr 27;102(9):1319-26. doi: 10.1038/sj.bjc.6605621.
9
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.神经母细胞瘤分子诊断的国际共识:国际神经母细胞瘤风险组(INRG)生物学委员会报告
Br J Cancer. 2009 May 5;100(9):1471-82. doi: 10.1038/sj.bjc.6605014.
10
MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.间碘苄胍闪烁扫描术用于神经母细胞瘤患儿的诊断与随访
Q J Nucl Med Mol Imaging. 2008 Dec;52(4):388-402.